GlassScriptPhysician profile
Catherine Sharbaugh
NPI 1689858912
$23,124.59
in general payments reported to CMS, 2019-2025
31 companies · $2,158 in 2025
The $2,158 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15K · 2022: $1,024 · 2023: $2,811 · 2024: $2,062 · 2025: $2,158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,243 · Consulting Fee: $788.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,242.73 |
| Consulting Fee | $787.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $14,631.93 | 2021-2024 | Xolair |
| Otsuka America Pharmaceutical, INC. | $1,141.30 | 2022-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Modernatx, INC. | $787.50 | 2023 | Moderna Covid-19 Vaccine |
| Gilead Sciences, INC. | $604.40 | 2022-2025 | Vemlidy, Livdelzi |
| Novo Nordisk INC | $594.55 | 2022-2023 | Wegovy |
| Sage Therapeutics, LLC | $455.85 | 2023-2024 | |
| Abbvie INC. | $398.64 | 2022-2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $395.65 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $373.64 | 2023-2024 | Uzedy, Austedo Xr |
| Mylan Specialty L.P. | $372.59 | 2023-2024 | Yupelri, Yupelri |
| Sumitomo Pharma America, INC. | $299.95 | 2023-2024 | Myfembree |
| Neurocrine Biosciences, INC. | $252.70 | 2021-2023 | Ingrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $247.14 | 2024-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $242.19 | 2025 | Entyvio |
| Alexion Pharmaceuticals, INC. | $238.44 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $227.60 | 2024-2025 | Tezspire, Wainua |
| Biohaven Pharmaceuticals, INC. | $220.39 | 2021 | |
| Madrigal Pharmaceuticals | $150.00 | 2025 | Rezdiffra |
| Ultragenyx Pharmaceutical INC. | $147.82 | 2023 | Crysvita |
| Biomerieux INC | $142.00 | 2025 | Biofire Respiratory Panel 2.1 |
| Phathom Pharmaceuticals, INC. | $130.23 | 2024 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $128.88 | 2025 | Cobenfy |
| Impel Pharmaceuticals INC. | $127.49 | 2023 | Trudhesa |
| Calliditas Therapeutics US INC. | $124.88 | 2023 | Tarpeyo |
| Axsome Therapeutics, INC. | $123.19 | 2025 | Auvelity |
| Viiv Healthcare Company | $121.92 | 2024 | Dovato |
| Scpharmaceuticals INC. | $121.91 | 2025 | |
| Amgen INC. | $111.84 | 2022 | |
| Sanofi-Aventis U.S. LLC | $100.01 | 2022 | |
| Lilly USA, LLC | $80.00 | 2023 | |
| Neurelis, INC. | $29.96 | 2024 | Valtoco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Sharbaugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.